Identifying and treating vision problems promptly can avert 90% of blindness. However, over 90% of individuals with asymptomatic retinal abnormalities fail to seek medical attention, resulting in an annual economic loss of approximately INR 90,000 Crores for the Indian economy.

Leveraging cutting-edge technologies such as Robotics, A.I. and 3D printing, the startup's state-of-the-art, multi-award-winning commercial devices and A.I. solutions address accessibility, affordability, availability, accuracy, and dependability in identifying individuals with retinal abnormalities. These innovations are applied for both in-clinic and mass screening within both private and public healthcare systems.

Revolutionizing eye care, the startup's solutions have screened over 2,00,000 individuals, detecting 32,000 with retinal abnormalities, notably in underserved rural areas. The unique hardware includes operator-independent Fundus screening and the world's most economical and portable OCT. A.I. capabilities offer high sensitivity and specificity, offline functionality, and precise identification of 19 retinal abnormalities, with an explainable A.I. highlighting affected areas, ensuring unmatched diagnostic accuracy and early intervention. This comprehensive approach prevents irreversible vision loss.

Over the next 3-5 years, the growth plan involves expanding retinal abnormality detection, submitting eight US FDA filings, predicting MI/stroke from fundus images, launching the world's most economical IOCT, SS OCT, and the first ROP OCT, aiming for a fivefold increase in sales and eightfold increase in profits within three years.